Background
Methods
Study groups
Diagnosis | Number (%) |
---|---|
Acute lymphoblastic leukemia (ALL) | 11 (40.7) |
Acute myeloblastic leukemia (AML) | 4 (14.8) |
Chronic myelocytic leukemia (CML) | 1 (3.6) |
Myelodysplastic syndrome (MDS) | 1 (3.6) |
Juvenile myelomonocytic leukemia (JMML) and AML | 1 (3.6) |
Neoplastic diseases – total | 18 (70) |
Severe aplastic anemia (SAA) | 4 (14.8) |
Chronic granulomatous disease (CGD) | 3 (8) |
Autoimmune lymphoproliferative syndrome (ALPS) | 1 (3.6) |
Hyper IgM syndrome (HIgM) | 1 (3.6) |
Non-neoplastic diseases – total | 9 (30) |
Type of HSCT | n (%) | Disease (n) |
---|---|---|
Allogeneic n = 27 (100%) | MUD - 16 (59) | ALL – 8 |
AML - 4 | ||
CML - 1 | ||
SAA - 1 | ||
CGD – 2 | ||
MSD - 9 (33) | ALL – 3 | |
SAA - 2 | ||
JMML and AML - 1 | ||
CGD - 1 | ||
HIgM - 1 | ||
MDS - 1 | ||
MFD - 2 (8) | SAA – 1 | |
ALPS - 1 |
Number of patients | 27 |
Sex | boys-20, girls-7 |
Age (years) | 1.5–19 (mean 9, median 9.6) |
Neoplastic diseases, n (n %) | 18 (67%) |
Chemotherapy before HSCT, n (n %) | 17 (63%) |
Local radiotherapy | 5 (CNS-4,Testes-1) |
Time since diagnosis (years) | |
Neoplastic diseases | Median-1, mean-2; range 0.1–7 |
Non-neoplastic diseases | Median-1.5, mean-3.8, range 0.1–13 |
Conditioning regimen based on busulfan or treosulfan, n (n %) | 16(60%) |
Total body irradiation – 12Gy/6fractions, n (n %) | 7 (26%) |
GvHD prophylaxis, n (n %) | |
CSA | 4 (15%) |
MTX + CSA | 23 (85%) |
Mucositis, n (%) | 22 (82%) |
Grade, n | I-7, II-8, III-6, IV-1 |
Intravenous alimentation due to mucositis (%) | 48 |
aGvHD, n (n %) | 11 (41) |
Localisation, % | Gut-9, Skin-91, Liver-27 |
Grade, n | IA-1, IB-4, IIB-1, IIC-3, IIIC-2 |
Systemic glucocorticoid treatment, n (%) | 19 (70) |
Systemic glucocorticoid treatment (days) | Median-3.5, mean-3.6; range 0.1–11 |
Time from discontinuation of systemic glucocorticoids to the second assessment (months) | Median-3.6, mean-4.5; range 0.5–14 |
Time from discontinuation of immunosuppressive treatment to the second assessment (months) | Median 1.6; range 0–9 |
Time from HSCT to the second assessment (months) | Median 6.3 (5.9–19.1) |
Anthropometric measurements
Study protocol
Laboratory measurements
Microarray analysis
Gene | Gene locus | Affimetrix code | Expression | p/ B-H | |
---|---|---|---|---|---|
Ghrelin | 3p26-p25 | 8,085,293 | post-HSCT 6.84 ± 0.41 | Control 6.99 ± 0.25 | 0.07/0.09 |
Cholecystocinin | 3p22-p21.3 | 8,086,391 | post-HSCT 5.61 ± 0.14 | Control 5.89 ± 0.23 | 0.0014/0.003 |
GLP-1 receptor | 6p21 | 8,119,338 | post-HSCT 6.26 ± 0.08 | Control 6.61 ± 0.27 | 0.0000/0.0001 |
FGF-21 | 19q13.1-qter | 8,030,105 | pre-HSCT 5.46 ± 0.15 | Control 5.59 ± 0.16 | 0.0395/0.4325 |
post-HSCT 5.36 ± 0.12 | Control 5.59 ± 0.16 | 0.0009/0.0021 |
Statistical analysis
Ethical issues
Results
Parameter | pre-HSCT | post-HSCT | Control | P value, pre-HSCT vs post-HSCT | P value, pre-HSCT vs control | P value, Post-HSCT vs control |
---|---|---|---|---|---|---|
BMIa | 18.9 (3.33) | 18.3 (3.47) | 19.1 (3.00) | 0.173 | 0.794 | 0.405 |
BMIPercb | 70.4 [44.9;86.4] | 51.0 [16.2;90.6] | 77.7 [46.7;84.3] | 0.170 | 0.967 | 0.486 |
BMISDSa | 0.57 (1.21) | 0.37 (1.26) | 0.61 (0.87) | 0.392 | 0.898 | 0.455 |
BF_kga | 6.46 (6.42) | 6.65 (5.35) | 12.0 (8.46) | 0.854 | 0.031 | 0.029 |
BF_%a | 14.5 (11.0) | 15.8 (8.71) | 21.1 (8.54) | 0.616 | 0.042 | 0.062 |